tazobactam has been researched along with ciprofloxacin in 57 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (ciprofloxacin) | Trials (ciprofloxacin) | Recent Studies (post-2010) (ciprofloxacin) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 16,060 | 1,331 | 6,092 |
| Protein | Taxonomy | tazobactam (IC50) | ciprofloxacin (IC50) |
|---|---|---|---|
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | 0.41 | |
| DNA gyrase subunit B | Bacillus subtilis subsp. subtilis str. 168 | 6.3 | |
| DNA gyrase subunit A | Bacillus subtilis subsp. subtilis str. 168 | 6.3 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.31 | |
| DNA gyrase subunit B | Staphylococcus aureus | 4.32 | |
| DNA gyrase subunit A | Escherichia coli K-12 | 0.6845 | |
| DNA gyrase subunit B | Escherichia coli K-12 | 0.5632 | |
| DNA topoisomerase 4 subunit B | Staphylococcus aureus | 6.485 | |
| DNA topoisomerase 4 subunit A | Staphylococcus aureus | 4.8011 | |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | 0.41 | |
| DNA gyrase subunit A | Staphylococcus aureus | 4.32 | |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | 0.41 | |
| DNA topoisomerase 4 subunit A | Bacillus subtilis subsp. subtilis str. 168 | 1.7 | |
| DNA topoisomerase 4 subunit B | Bacillus subtilis subsp. subtilis str. 168 | 1.7 | |
| GABA theta subunit | Rattus norvegicus (Norway rat) | 0.41 | |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | 0.41 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (26.32) | 18.2507 |
| 2000's | 16 (28.07) | 29.6817 |
| 2010's | 17 (29.82) | 24.3611 |
| 2020's | 9 (15.79) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Bonnet, R; Caniça, M; Ferreira, E; Manageiro, V; Mendonça, N; Robin, F; Salgado, MJ | 1 |
| Cauda, R; D'Inzeo, T; De Pascale, G; Fadda, G; Fiori, B; Leone, F; Rossi, M; Sali, M; Sanguinetti, M; Spanu, T; Trecarichi, EM; Tumbarello, M | 1 |
| Andlovic, A; Jeverica, S; Karisik, E; Koren, S; Krizan-Hergouth, V; Livermore, DM; Mesko Meglic, K; Müller-Premru, M; Palepou, MF; Pike, R; Seme, K; Woodford, N | 1 |
| Bonnet, R; Casin, I; Doublet, B; Fabre, L; Le Fleche, A; Robin, F; Weill, FX | 1 |
| Choi, JY; Ko, KS; Lee, MY; Park, YK; Peck, KR; Rhee, JY; Shin, JY; Song, JH | 1 |
| Chan, MC; Chang, TY; Chiueh, TS; Sun, JR; Wang, WY | 1 |
| Aldridge, KE; Barry, AL; Gelfand, MS; Jones, RN | 1 |
| Blakemore, PH; Drabu, YJ; Mehtar, S | 1 |
| Hyatt, JM; Nix, DE; Schentag, JJ; Stratton, CW | 1 |
| Cantrell, HF; Lankford, RB; Murray, PR | 1 |
| Appelbaum, PC; Jacobs, MR; Spangler, SK | 2 |
| Arpi, M; Bruun, B; Gottschau, A; Mortensen, I; Victor, MA | 1 |
| Bowker, KE; Hedges, AJ; Holt, HA; MacGowan, AP; Reeves, DS; Wootton, M | 1 |
| Knapp, CC; Ludwig, MD; Pohlman, JK; Washington, JA | 1 |
| Gould, IM; Milne, K | 1 |
| Constantoulaki, S; Paniara, O; Platsouka, E; Zissis, NP | 1 |
| Adhikari, M; Pillay, DG; Pillay, T; Sturm, AW | 1 |
| Andremont, A; Guy, H; Marie, JP; Pico, JL; Richet, H; Vekhoff, A | 1 |
| Babini, GS; Bates, J; Livermore, DM; Palepou, MF; Woodford, N | 1 |
| Forrest, A; Nix, DE; Schentag, JJ; Strenkoski-Nix, LC | 1 |
| Burgess, DS; Hastings, RW | 1 |
| Adinolfi, LE; Andreana, A; Casillo, R; Durante Mangoni, E; Farina, C; Gambardella, M; Sarnataro, G; Tripodi, MF; Utili, R | 1 |
| Jones, RN; Mutnick, AH; Turner, PJ | 1 |
| Burgess, DS; Nathisuwan, S | 1 |
| Berardi, B; Callea, A; Cormio, L; Fiorentino, N; Sblendorio, D; Traficante, A; Zizzi, V | 1 |
| Finsterer, J; Kotzailias, N | 1 |
| Jakoniuk, P; Leszczyńska, K; Sacha, PT; Wieczorek, P; Zalewska, M | 1 |
| Ashkenazi, S; Bishara, J; Lev, B; Levy, I; Livne, G; Ofir, O; Pitlik, S; Samra, Z | 1 |
| Pang, XY; Tian, BW; Yang, YJ | 1 |
| Hashikita, G; Kawakami, S; Kobayashi, S; Maesaki, S; Nagasawa, M; Okabe, T; Sasaki, K; Shibuya, S; Suzuki, N; Takayama, S; Uchida, T; Watanabe, M; Yamaguchi, T | 1 |
| Bennett, KM; Dodds-Ashley, E; Hayward, TZ; Kaye, KS; Scarborough, JE; Sharpe, M; Vaslef, SN | 1 |
| Aldeyab, MA; Bailie, R; Elshibly, SM; Hanley, J; Hughes, CM; Kearney, MP; McDowell, DA; McElnay, JC; McMahon, MA; Scott, MG | 1 |
| Dundar, D; Otkun, M | 1 |
| Luetzke, A; Ruebben, H; Schenck, M; Schneider, T | 1 |
| Blahut, L; Hricová, K; Kolár, M; Neiser, J; Urbánek, K; Uvízl, R; Vojtová, V | 1 |
| Bellomo, R; Cole, L; Lipman, J; Liu, X; Nair, P; Roberts, DM; Roberts, JA; Roberts, MS | 1 |
| Hansson, J; Johnsson, E; Jönsson, C; Körner, U; Ludwigs, K; Lundholm, K | 1 |
| Andersson, RE; Schein, M | 1 |
| Fortier, LC; Garneau, JR; Valiquette, L | 1 |
| Frey, L; Maier, B; Suhr, A; Teupser, D; Vogeser, M; Zander, J; Zoller, M | 1 |
| Du, Y; Guo, W; He, J; He, Q; Wang, Z; Wei, M; Wu, C; Yang, Z | 1 |
| Chen, Y; Gao, W; Li, X; Ouyang, W; Wei, J; Wen, Z; Xue, H | 1 |
| Banerjee, R; Boyce, TG; Cunningham, SA; Hasassri, ME; Jeraldo, PR; Kaye, KS; Norgan, AP; Patel, R; Pogue, JM; Weissman, SJ | 1 |
| Abdel-Haq, N; Ang, JY; Nicolau, DP; Satlin, MJ; Thabit, AK; van Duin, D; Zhu, F | 1 |
| Goodlet, KJ; Nailor, MD; Nicolau, DP | 1 |
| Bischoff, S; Ebert, M; Gerigk, M; Vogelmann, R; Walter, T | 1 |
| Boulanger, B; Cizeau, F; Decousser, JW; Ducellier, D; Fourreau, F; Mercier-Darty, M; Mongardon, N; Podglajen, I; Potron, A; Royer, G | 1 |
| Adams, R; Agus, A; Barnes, RA; Chau, I; Clarke, M; Coyle, V; Doran, A; Forde, C; Grayson, M; McAuley, DF; McDowell, C; McMullan, R; Plummer, R; Thomas, AL; Wilson, RH | 1 |
| Elmas, Ç; Erdal, B; Yalınay, M; Yazıcı, GN | 1 |
| Sivashanmugam, K; Srivastava, P | 1 |
| Alcaraz-Serrano, V; Amaro, R; Bueno-Freire, L; Cabrera, R; Fernández-Barat, L; López-Aladid, R; Muñoz, L; Oscanoa, P; Torres, A; Vázquez, N; Vila, J | 1 |
| Güler, N; Süleyman, A; Tamay, Z | 1 |
| Deligios, M; Fiamma, M; Paglietti, B; Rubino, S; Sacarlal, J; Santona, A; Simbine, SE; Sumbana, JJ; Taviani, E; Zimba, T | 1 |
| Dong, L; Feng, J; Geng, H; Gu, S; He, C; Hou, G; Ji, T; Kang, W; Lai, J; Li, Y; Li, Z; Pang, D; Wang, Y; Zhao, L; Zhu, X; Zhu, Y | 1 |
| Caljon, B; Crombé, F; De Geyter, D; Demuyser, T; Janssen, T; Muyldermans, A; Piérard, D; Seyler, L; Vanstokstraeten, R; Wybo, I | 1 |
5 trial(s) available for tazobactam and ciprofloxacin
| Article | Year |
|---|---|
Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Therapy, Combination; Fever; Hematologic Neoplasms; Humans; Multivariate Analysis; Neutropenia; Opportunistic Infections; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin | 1998 |
Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers.
Topics: Adolescent; Adult; Anti-Infective Agents; Area Under Curve; Ciprofloxacin; Cross-Over Studies; Drug Interactions; Enzyme Inhibitors; Female; Humans; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Tazobactam | 1998 |
Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs piperacillin/tazobactam.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Bacterial Infections; Biopsy; Ciprofloxacin; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Injections, Intramuscular; Male; Penicillanic Acid; Penicillins; Piperacillin; Postoperative Complications; Prospective Studies; Prostatic Diseases; Tazobactam; Transurethral Resection of Prostate | 2002 |
[Perioperative antibiotic prophylaxis in radical retropubic prostatectomy: a randomised pilot study of perioperative and postoperative administration].
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Body Temperature; C-Reactive Protein; Ciprofloxacin; Drug Administration Schedule; Drug Therapy, Combination; Humans; Infusions, Intravenous; Length of Stay; Male; Middle Aged; Neoplasm Staging; Penicillanic Acid; Perioperative Care; Pilot Projects; Piperacillin; Postoperative Complications; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Surgical Wound Infection; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2011 |
Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Ciprofloxacin; Cost-Benefit Analysis; Drug Administration Schedule; Equivalence Trials as Topic; Humans; Meropenem; Multicenter Studies as Topic; Neoplasms; Neutropenia; Piperacillin; Pragmatic Clinical Trials as Topic; Quality of Life; Sepsis; Tazobactam; Treatment Outcome | 2020 |
52 other study(ies) available for tazobactam and ciprofloxacin
| Article | Year |
|---|---|
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
The Lys234Arg substitution in the enzyme SHV-72 is a determinant for resistance to clavulanic acid inhibition.
Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Arginine; Aztreonam; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Cephalosporins; Clavulanic Acid; Computer Simulation; Imipenem; Isoelectric Focusing; Kinetics; Klebsiella pneumoniae; Lysine; Microbial Sensitivity Tests; Models, Molecular; Molecular Sequence Data; Penicillins; Protein Conformation; Protein Structure, Tertiary | 2008 |
Bloodstream infections caused by extended-spectrum-beta-lactamase- producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Risk Factors; Treatment Failure | 2008 |
Nationwide survey of CTX-M-type extended-spectrum beta-lactamases among Klebsiella pneumoniae isolates in Slovenian hospitals.
Topics: Anti-Bacterial Agents; beta-Lactamases; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Hospitals; Klebsiella pneumoniae; Microbial Sensitivity Tests; Slovenia | 2009 |
Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Catheters, Indwelling; Chromosomes, Bacterial; Cloning, Molecular; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Genetic Variation; Isoelectric Focusing; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Plasmids; Pseudomonas; Pseudomonas Infections; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Substrate Specificity | 2010 |
KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
Topics: Aged; beta-Lactamases; Diabetic Nephropathies; Humans; Kidney Failure, Chronic; Klebsiella Infections; Klebsiella pneumoniae; Male; Renal Dialysis; Republic of Korea | 2010 |
Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Aged; Aged, 80 and over; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Female; Humans; Male; Membrane Transport Proteins; Middle Aged; Minocycline; Molecular Sequence Data; Mutagenesis, Insertional; Reverse Transcriptase Polymerase Chain Reaction; Tigecycline | 2010 |
In vitro activity of various antimicrobial agents against Staphylococcus aureus isolates including fluoroquinolone- and oxacillin-resistant strains.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Resistance, Microbial; Microbial Sensitivity Tests; Oxacillin; Penicillanic Acid; Staphylococcus aureus; Tazobactam | 1992 |
The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria.
Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Citrobacter; Drug Resistance, Microbial; Enterobacteriaceae; Gram-Negative Bacteria; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Serratia; Tazobactam | 1990 |
In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa.
Topics: Anti-Infective Agents; Bacteria; Ciprofloxacin; Drug Therapy, Combination; Enterobacter cloacae; Enzyme Inhibitors; Klebsiella pneumoniae; Least-Squares Analysis; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Tazobactam; Time Factors | 1995 |
Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected beta-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gram-negative bacteria. In Vitro Susceptibility Surveilla
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Ciprofloxacin; Gram-Negative Bacteria; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1994 |
Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Cefoxitin; Ciprofloxacin; Fluoroquinolones; Metronidazole; Microbial Sensitivity Tests; Naphthyridines; Penicillanic Acid; Piperacillin; Piperazines; Quinolones; Tazobactam | 1994 |
In vitro susceptibility of 124 Xanthomonas maltophilia (Stenotrophomonas maltophilia) isolates: comparison of the agar dilution method with the E-test and two agar diffusion methods.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Ceftazidime; Ciprofloxacin; Enzyme Inhibitors; Escherichia coli; Gentamicins; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Staphylococcus aureus; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination; Xanthomonas | 1996 |
A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative beta-lactam, aminoglycoside and fluoroquinolone.
Topics: Acinetobacter; Ciprofloxacin; Citrobacter freundii; Drug Therapy, Combination; Enterobacteriaceae; Gentamicins; Microbial Sensitivity Tests; Models, Biological; Penicillanic Acid; Piperacillin; Serratia marcescens; Tazobactam | 1996 |
Timed killing kinetic studies of the interaction between ciprofloxacin and beta-lactams against gram-negative bacilli.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aztreonam; Ceftazidime; Cephalosporins; Ciprofloxacin; Clavulanic Acid; Clavulanic Acids; Drug Interactions; Drug Therapy, Combination; Enterobacter cloacae; Enzyme Inhibitors; Kinetics; Klebsiella pneumoniae; Microbial Sensitivity Tests; Monobactams; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Serratia marcescens; Tazobactam; Ticarcillin; Time Factors | 1996 |
In-vitro pharmacodynamic studies of piperacillin/tazobactam with gentamicin and ciprofloxacin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; beta-Lactamase Inhibitors; Ciprofloxacin; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Gentamicins; Kinetics; Macrolides; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Tazobactam | 1997 |
Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and piperacillin/tazobactam against six anaerobes.
Topics: Anti-Infective Agents; Bacteroides; Bacteroides fragilis; Cefoxitin; Ciprofloxacin; Clostridium perfringens; Fluoroquinolones; Fusobacterium; Gram-Negative Anaerobic Bacteria; Metronidazole; Microbial Sensitivity Tests; Naphthyridines; Penicillanic Acid; Peptostreptococcus; Piperacillin; Prevotella melaninogenica; Quinolones; Tazobactam | 1997 |
Comparative in vitro evaluation of piperacillin/tazobactam in a tertiary care hospital.
Topics: Amoxicillin; Ceftazidime; Cephalosporin Resistance; Cephalosporins; Ciprofloxacin; Clavulanic Acid; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Intensive Care Units; Microbial Sensitivity Tests; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Tazobactam | 1997 |
Piperacillin/tazobactam in the treatment of Klebsiella pneumoniae infections in neonates.
Topics: Anti-Infective Agents; beta-Lactamase Inhibitors; Cilastatin; Ciprofloxacin; Cross Infection; Drug Combinations; Drug Resistance, Microbial; Drug Resistance, Multiple; Enzyme Inhibitors; Female; Humans; Imipenem; Infant, Newborn; Klebsiella Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Protease Inhibitors; Retrospective Studies; Tazobactam; Thienamycins | 1998 |
Carbapenemase-producing Pseudomonas aeruginosa in UK.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Enzyme Inhibitors; Gentamicins; Humans; Imipenem; Meropenem; Metalloproteins; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; United Kingdom | 1998 |
Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Chi-Square Distribution; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fluoroquinolones; Humans; Naphthyridines; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2000 |
Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies.
Topics: Adult; Anti-Bacterial Agents; Bronchoalveolar Lavage; Ciprofloxacin; Female; Heart Transplantation; Humans; Lung Diseases; Male; Microbial Sensitivity Tests; Middle Aged; Nocardia; Nocardia Infections; Penicillanic Acid; Piperacillin; Postoperative Complications; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2001 |
Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection.
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Critical Care; Cystic Fibrosis; Data Collection; Drug Resistance, Bacterial; Europe; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Neutropenia; Penicillanic Acid; Piperacillin; Population Surveillance; Proteus Infections; Proteus mirabilis; Tazobactam; Thienamycins | 2002 |
Cefepime, piperacillin/tazobactam, gentamicin, ciprofloxacin, and levofloxacin alone and in combination against Pseudomonas aeruginosa.
Topics: Cefepime; Cephalosporins; Ciprofloxacin; Drug Resistance, Microbial; Drug Therapy, Combination; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sensitivity and Specificity; Tazobactam | 2002 |
Thrombocytosis under ciprofloxacin and tazobactam/piperacillin.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Therapy, Combination; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Platelet Count; Pneumonia, Bacterial; Tazobactam; Thrombocytosis | 2003 |
[Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens].
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamases; Cefotaxime; Ceftazidime; Ciprofloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Thienamycins; Ticarcillin | 2004 |
Antibacterial susceptibility of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
Topics: Adult; Amikacin; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; beta-Lactamases; Child; Ciprofloxacin; Clavulanic Acid; Drug Resistance, Bacterial; Enzyme Inhibitors; Escherichia coli; Humans; In Vitro Techniques; Israel; Klebsiella pneumoniae; Microbial Sensitivity Tests; Odds Ratio; Penicillanic Acid; Piperacillin; Prevalence; Tazobactam | 2005 |
[Dynamic analysis of drug resistance of Pseudomonas aeruginosa in laboratory and clinical two-drug regimen].
Topics: Amikacin; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam; Tazobactam | 2005 |
[The combination effects of antibacterial agents against clinical isolated multiple-drug resistant Pseudomonas aeruginosa].
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Cefepime; Cefoperazone; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Meropenem; Microbial Sensitivity Tests; Oxazines; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam; Thienamycins | 2006 |
Implementation of antibiotic rotation protocol improves antibiotic susceptibility profile in a surgical intensive care unit.
Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Clinical Protocols; Critical Care; Cross Infection; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Incidence; Intensive Care Units; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Probability; Retrospective Studies; Sensitivity and Specificity; Tazobactam; Treatment Outcome | 2007 |
Comparison of the effect of ciprofloxacin and Tazocin on the incidence of meticillin-resistant Staphylococcus aureus (MRSA) in an Intensive Care Unit.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Ciprofloxacin; Cross Infection; Data Interpretation, Statistical; Drug Combinations; Electrophoresis, Gel, Pulsed-Field; Hand Disinfection; Hygiene; Intensive Care Units; Methicillin-Resistant Staphylococcus aureus; Penicillanic Acid; Personnel, Hospital; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcal Infections; Tazobactam | 2008 |
In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.
Topics: Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Synergism; Imipenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Tobramycin | 2010 |
Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units.
Topics: Amikacin; Anti-Bacterial Agents; Cefoperazone; Ceftazidime; Ciprofloxacin; Czech Republic; Drug Resistance, Multiple, Bacterial; Gentamicins; Intensive Care Units; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Sulbactam; Tazobactam | 2011 |
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Ciprofloxacin; Critical Illness; Female; Hemofiltration; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Tazobactam; Thienamycins; Vancomycin | 2012 |
Antibiotics as first-line therapy for acute appendicitis: evidence for a change in clinical practice.
Topics: Acute Disease; Administration, Intravenous; Administration, Oral; Adult; Anti-Bacterial Agents; Appendicitis; Ciprofloxacin; Female; Humans; Male; Metronidazole; Penicillanic Acid; Piperacillin; Prospective Studies; Randomized Controlled Trials as Topic; Tazobactam | 2012 |
Antibiotics as first-line therapy for acute appendicitis: evidence for a change in clinical practice.
Topics: Anti-Bacterial Agents; Appendicitis; Ciprofloxacin; Female; Humans; Male; Metronidazole; Penicillanic Acid; Piperacillin; Tazobactam | 2012 |
Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Clostridioides difficile; Humans; Metronidazole; Microbial Sensitivity Tests; Minocycline; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Ribotyping; Spores, Bacterial; Tazobactam; Tigecycline; Vancomycin | 2014 |
Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation.
Topics: Analytic Sample Preparation Methods; Anti-Bacterial Agents; Automation; Blood Chemical Analysis; Cefepime; Cephalosporins; Chromatography, High Pressure Liquid; Ciprofloxacin; Humans; Isotopes; Linezolid; Meropenem; Penicillanic Acid; Piperacillin; Tandem Mass Spectrometry; Tazobactam; Thienamycins; Time Factors | 2015 |
Influence of antimicrobial consumption on gram-negative bacteria in inpatients receiving antimicrobial resistance therapy from 2008-2013 at a tertiary hospital in Shanghai, China.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Ceftazidime; China; Ciprofloxacin; Cross Infection; Drug Resistance, Multiple, Bacterial; Drug Utilization Review; Escherichia coli; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Inpatients; Klebsiella pneumoniae; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Tertiary Care Centers | 2015 |
Clinical characteristics and antimicrobial patterns in complicated intra-abdominal infections: a 6-year epidemiological study in southern China.
Topics: Anti-Bacterial Agents; Carbapenems; China; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Enterococcus faecalis; Epidemiologic Studies; Escherichia coli; Female; Gentamicins; Humans; Intraabdominal Infections; Klebsiella pneumoniae; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Tazobactam; Treatment Outcome | 2016 |
An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ciprofloxacin; Ertapenem; Escherichia coli; Female; Gentamicins; Humans; Immunocompromised Host; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins; Tobramycin | 2016 |
Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; beta-Lactams; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Female; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Humans; Iatrogenic Disease; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tazobactam; Thienamycins; Tobramycin | 2017 |
Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Area Under Curve; Cephalosporins; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Emergency Service, Hospital; Female; Fluoroquinolones; Gentamicins; Germany; Humans; Male; Middle Aged; Odds Ratio; Penicillanic Acid; Piperacillin; Risk Factors; ROC Curve; Tazobactam; Urinary Tract Infections | 2018 |
Local outbreak of extended-spectrum β-lactamase SHV2a-producing Pseudomonas aeruginosa reveals the emergence of a new specific sub-lineage of the international ST235 high-risk clone.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Ciprofloxacin; Colistin; Cross Infection; Disease Outbreaks; Drug Combinations; Drug Resistance, Multiple, Bacterial; Female; France; Humans; Microbial Sensitivity Tests; Multilocus Sequence Typing; Polymorphism, Single Nucleotide; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2020 |
[Investigation of Pseudomonas aeruginosa Biofilm Formation and Quorum Sensing Genes in Piperacillin/Tazobactam and Ciprofloxacin Sub-minimal Inhibitory Concentrations].
Topics: Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Ciprofloxacin; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Quorum Sensing; Tazobactam | 2020 |
Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Diabetic Foot; Drug Resistance; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Resistance mechanisms and molecular epidemiology of Pseudomonas aeruginosa strains from patients with bronchiectasis.
Topics: Anti-Bacterial Agents; beta-Lactamases; Bronchiectasis; Ceftazidime; Ciprofloxacin; Humans; Microbial Sensitivity Tests; Molecular Epidemiology; Multilocus Sequence Typing; Phylogeny; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2022 |
Antibiotic allergy in children with cystic fibrosis: A retrospective case-control study.
Topics: Amikacin; Anti-Bacterial Agents; Azithromycin; Case-Control Studies; Ceftazidime; Child; Ciprofloxacin; Cystic Fibrosis; Drug Hypersensitivity; Humans; Levofloxacin; Meropenem; Piperacillin; Retrospective Studies; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
High-risk lineages among extended-spectrum β-lactamase-producing Escherichia coli from extraintestinal infections in Maputo Central Hospital, Mozambique.
Topics: Amoxicillin; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefotaxime; Ceftazidime; Ciprofloxacin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Extraintestinal Pathogenic Escherichia coli; Gentamicins; Hospitals; Humans; Iron; Mozambique; Piperacillin; Tazobactam; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Drug resistance characteristics and molecular typing of Escherichia coli isolates from neonates in class A tertiary hospitals: A multicentre study across China.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Carbapenems; Cefotaxime; Child; Ciprofloxacin; Doxycycline; Drug Resistance; Escherichia coli; Escherichia coli Infections; Female; Humans; Infant, Newborn; Microbial Sensitivity Tests; Multilocus Sequence Typing; Piperacillin; Pregnancy; Tazobactam; Tertiary Care Centers; Trimethoprim, Sulfamethoxazole Drug Combination | 2022 |
Genotypic resistance determined by whole genome sequencing versus phenotypic resistance in 234 Escherichia coli isolates.
Topics: Amikacin; Amoxicillin; Anti-Bacterial Agents; Cefepime; Cefotaxime; Ceftazidime; Ciprofloxacin; Clavulanic Acid; Escherichia coli; Escherichia coli Infections; Genotype; Gentamicins; Humans; Meropenem; Microbial Sensitivity Tests; Phenotype; Piperacillin; Retrospective Studies; Tazobactam; Tobramycin; Whole Genome Sequencing | 2023 |